| CAS No.: | 1985606-14-1 |
|---|---|
| Formula: | C27h23f2n3o7s |
| EINECS: | 606-227-7 |
|
Still deciding? Get samples of US$ 1/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Baloxavir marboxil
Xofluza;S-033188 ; (3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-Chemicalbook10,13-dien-11-yl]oxymethylmethylcarbonate; CS-2794; Baloxavirester; Balosavirester; S-033188;XOFLUZA;Baloxavirmarboxi;aloxavirmarboxil;2'S)-Folinicacid
Baloxavir marboxil is an antiviral drug developed by Shionogi Co., a Japanese pharmaceutical company and Roche for the treatment of influenza A and influenza B infections. The drug was initially approved for use in Japan in February 2018 and approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours Label. Baloxavir marboxil, a cap-endonuclease inhibitor, has a unique mechanism of action when compared to the currently existing neuraminidase inhibitor drug class used to treat influenza infections.
| Chemical Name | Baloxavir marboxil |
| CAS | 1985606-14-1 |
| Molecular Formula | C27H23F2N3O7S |
| Molecular Weight | 571.55 |
| Appearance | white powder |
| Color | white |
| Brand Name | Megawide |
Baloxavir marboxil is an influenza medication, an antiviral,that is taken as a single dose tablet,by mouth, by individuals that are 12 years of age or older,that have presented symptoms of this infection for no more than 48 hours.The efficacy of baloxavir marboxil administered after 48 hours has not been tested.
Packaging Detail: 25 Kg Paper Bag or as The Request of Customer.
Delivery Detail:
){kind=link}